Management of extraintestinal manifestations and other complications of inflammatory bowel disease

Current Gastroenterology Reports

Volumn 6, Issue 6, 2004, Pages 506-513

  Loftus Jr , Edward V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; FLUORIDE SODIUM; HLA DR ANTIGEN; IBANDRONIC ACID; IMMUNOGLOBULIN A ANTIBODY; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; ROFECOXIB; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; URSODEOXYCHOLIC ACID; VITAMIN D;

ANKYLOSING SPONDYLITIS; ANTIBODY TITER; APPENDECTOMY; ARTHRITIS; AUTOIMMUNE DISEASE; CANCER RISK; CIGARETTE SMOKING; CLINICAL TRIAL; COLORECTAL SURGERY; COLORECTAL TUMOR; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; ENTERITIS; ENVIRONMENTAL FACTOR; ERYTHEMA NODOSUM; EYE DISEASE; FRACTURE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEPATOBILIARY DISEASE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; LONG TERM CARE; META ANALYSIS; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PATHOGENESIS; POPULATION RESEARCH; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PYODERMA GANGRENOSUM; REVIEW; RISK FACTOR; RISK REDUCTION; SACROILIITIS; SIDE EFFECT; SKIN DISEASE; SPONDYLOARTHROPATHY; SYSTEMIC DISEASE; THROMBOEMBOLISM; TREATMENT FAILURE; TUBERCULOSIS; ULCERATIVE COLITIS; VITAMIN SUPPLEMENTATION;

EID: 9944222738     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-004-0073-7     Document Type: Review

References (96)

1. Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714-718.
2. Ricart E, Panaccione R, Loftus EV, et al.: Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study Inflamm Bowel Dis 2004, 10:207-14.
3. Manguso F, Sanges M, Staiano T, et al.: Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 2004, 99:327-334.
4. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. and the European Collaborative for IBDSG: Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001, 36:1307-1313.
5. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96: 116-1122.
6. Palm O, Moum B, Ongre A, Gran JT: Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002, 29:511-515.
7. Steer S, Jones H, Hibbert J, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003, 30:518-522.
8. Mielants H, Veys E, Cuvelier C, De Vos M: HLA B27 related arthritis and bowel inflammation. II. Ileocolonoscopy and bowel histology in patients with HLA B27 related arthritis. J Rheumatol 1985, 12:294-298.
9. De Vos M, Mielants H, Cuvelier C, et al.: Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996, 110:1696-1703.
10. Bjarnason I, Helgason KO, Geirsson AJ, et al.: Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003, 125:1598-1605.
11. Hoffman IE, Demetter P, Peeters M, et al.: Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003, 62:455-459.
12. Miceli-Richard C, Zouali H, Lesage S, et al.: CARD 15/NOD2 analyses in spondylarthropathy. Arthritis Rheum 2002, 46:1405-1406.
13. Ferreiros-Vidal I, Amarelo J, Barros F, et al.: Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J Rheumatol 2003, 30:102-104.
14. van der Paardt M, Crusius JB, de Koning MH, et al.: CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 2003, 4:77-78.
15. De Vos M, Laukens D, Marichal D, et al.: CARD 15 mutations in patients with spondyloarthropathy are linked with disease progression and evolution to Crohn's disease [abstract]. Gastroenterology 2003, 124:A48.
16. Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
17. Braun J, Brandt J, Listing J, et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233.
18. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349-1356.
19. Brandt J, Khariouzov A, Listing J, et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667-1675.
20. Davis JC Jr, Van Der Heijde D, Braun J, et al., and the Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48: 230-3236.
21. Maksymowych WP, Inman RD, Gladman D, et al., and the Spondyloarthritis Research Consortium of Canada (SPARCC): Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003, 30:1356-1363.
22. Palm O, Moum B, Jahnsen J, Gran JT: The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology 2001, 40:1256-1261.
23. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387-391.
24. Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274-278.
25. Balbir-Gurman A, Schapira D, Nahir M: Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis Semin Arthritis Rheum 2001, 30:242-248.
26. Reinisch W, Miehsler W, Dejaco C, et al.: An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003, 17:1371-1380.
27. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ: Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002, 97:910-914.
28. Menachem Y, Gotsman I: Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004, 6:88-90.
29. Newman B, Cescon D, Domenchini A, Siminovitch KA: CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. J Invest Dermatol 2004, 122:1054-1056.
30. Vidal D, Alomar A: Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. Br J Dermatol 2004, 150:387-388.
31. Ljung T, Staun M, Grove O, et al.: Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002, 37:1108-1110.
32. Kugathasan S, Miranda A, Nocton J, et al.: Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003, 37:150-154.
33. Regueiro M, Valentine J, Plevy S, et al.: Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98:1821-1826.
34. Mintz R, Feller ER, Bahr RL, Shah SA: Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135-139.
35. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003, 30: 277-1279.
36. Kaplan-Messas A, Barkana Y, Avni I, Neumann R: Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocular Immunol Inflamm 2003, 11: 31-139.
37. Baltatzis S, Tufail F, Yu EN, et al.: Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003, 110:1061-1065.
38. Lau CH, Comer M, Lightman S: Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation Clin Exp Ophthalmol 2003, 31:487-491.
39. Joseph A, Raj D, Dua HS, et al.: Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003, 110:1449-1453.
40. Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352-356.
41. Reiff A: Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 2003, 48:2079-2080.
42. Foster CS, Tufail F, Waheed NK, et al.: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate Arch Ophthalmol 2003, 121:437-440.
43. Murphy CC, Greiner K, Plskova J, et al.: Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004, 122:845-851.
44. Nussenblatt RB, Thompson DJ, Li Z, et al.: Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003, 21:283-293.
45. Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786-789.
46. Bambha K, Kim WR, Talwalkar J, et al.: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125: 364-1369.
47. Florin TH, Pandeya N, Radford-Smith GL: Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 2004, 53:973-979.
48. Perdigoto R, Wiesner RH, LaRusso NF, Dozois R: Inflammatory bowel disease associated with primary sclerosing cholangitis: incidence, severity and relationship to liver disease [abstract]. Gastroenterology 1991, 100:A238.
49. Harewood GC, Loftus EV, Tremaine WJ, Sandborn WJ: 'PSC-IBD': a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis [abstract]. Gastroenterology 1999, 116:A732.
50. Loftus EV, Harewood GC, Loftus CG, et al.: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2004, in press.
51. Boberg KM, Egeland T, Schrumpf E: Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003, 38:991-995.
52. Epstein MP, Kaplan MM: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004, 49:1-4.
53. Haagsma EB, Van Den Berg AP, Kleibeuker JH, et al.: Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003, 18:33-44.
54. Vera A, Gunson BK, Ussatoff V, et al.: Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003, 75:1983-1988.
55. Bernstein CN, Leslie WD, Leboff MS: AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
56. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791-794.
57. Bernstein CN, Katz S: Osteoporosis and Inflammatory Bowel Disease: A Guide to Diagnosis and Management for the Gastroenterologist Arlington, VA: American College of Gastroenterology; 2002.
58. Jahnsen J, Falch JA, Mowinckel P, Aadland E: Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004, 39:145-153.
59. Hanley DA, Brown JP, Tenenhouse A, et al., and the Canadian Multicentre Osteoporosis Study Research Group: Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003, 18:784-790.
60. de Jong DJ, Mannaerts L, van Rossum LG, et al.: Longitudinal study of bone mineral density in patients with Crohn's disease. Dig Dis Sci 2003, 48:1355-1359.
61. Bernstein CN, Leslie WD, Taback SP: Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol 2003, 98: 094-1100.
62. Bernstein CN, Bector S, Leslie WD: Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003, 98:2468-2473.
63. Siffledeen JS, Siminoski K, Steinhart H, et al.: The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol 2003, 17:473-478.
64. Bernstein CN, Blanchard JF, Leslie W, et al.: The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000, 133: 95-799.
65. Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1-10.
66. Loftus EV Jr, Crowson CS, Sandborn WJ, et al.: Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002, 123:468-475.
67. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al.: Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2003, l:465-473.
68. van Staa TP, Cooper C, Brusse LS, et al.: Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591-1597.
69. Card T, West J, Hubbard R, Logan RF: Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004, 53:251-255.
70. Bernstein CN, Blanchard JF, Metge C, Yogendran M: The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003, 98:1797-1801.
71. Bartram SA, Peaston RT, Rawlings DJ, et al.: A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1121-1127.
72. von Tirpitz C, Klaus J, Steinkamp M, et al.: Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003, 17:807-816.
73. Papa A, Danese S, Grillo A, et al.: Review article: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003, 98:1247-1251.
74. Bernstein CN, Blanchard JF, Houston DS, Wajda A: The incidence of deep venous thrombosis and pulmonary embolism, among patients with inflammatory bowel disease: a population-based cohort study Thromb Haemost 2001, 85:430-434.
75. Miehsler W, Reinisch W, Valic E, et al.: Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004, 53:542-548.
76. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ: Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004, 99:97-101.
77. Papa A, Danese S, Piccirillo N, et al.: Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. Hepatogastroenterology 2003, 50:132-135.
78. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48: 26-535.
79. Soetikno RM, Lin OS, Heidenreich PA, et al.: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
80. Lakatos L, Mester G, Erdelyi Z, et al.: Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004, 10:404-409.
81. Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103:1444-1451.
82. Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993, 105:1716-1723.
83. Jess T, Winther KV, Munkholm P, et al.: Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004, 19:287-293.
84. Winther KV, Jess T, Langholz E, et al.: Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004, in press.
85. Chen R, Rabinovitch PS, Crispin DA, et al.: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 2003, 162:665-672.
86. Lashner BA, Bauer WM, Rybicki LA, Goldblum JR: Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Am J Gastroenterol 2003, 98:1423-1427.
87. Kiesslich R, Fritsch J, Holtmann M, et al.: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003, 124:880-888.
88. Hurlstone DP, McAlindon ME, Sanders DS, et al.: Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2004, 126:376-378.
89. Ullman T, Croog V, Harpaz N, et al.: Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003, 125:1311-1319.
90. Ullman TA, Loftus EV Jr, Kakar S, et al.: The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002, 97:922-927.
91. Rubin DT, Djordjevic A, Huo D, et al.: Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis [abstract]. Gastroenterology 2003, 124: 36.
92. van Staa TP, Card T, Leufkens HGM, Logan RF: Prior aminosalicylate use and the development of colorectal cancer in inflammatory bowel disease (IBD): a large British epidemiological study [abstract]. Am J Gastroenterol 2003, 98:S244-S245.
93. Bernstein CN, Blanchard JF, Metge C, Yogendran M: Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003, 98:2784-2788
94. Rutter M, Saunders B, Wilkinson K, et al.: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
95. Velayos FS, Walsh JME, Terdiman JP: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk in ulcerative colitis: a meta-analysis [abstract]. Gastroenterology 2004, 126:A20.
96. Pardi DS, Loftus EV Jr, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.